# Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

> **NCT00515203** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 22 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura
- Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

## Interventions

- **DRUG:** Placebo
- **DRUG:** AMG 531

## Key facts

- **NCT ID:** NCT00515203
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-03
- **Final completion:** 2009-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515203, "Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00515203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*